Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6640189 | 0.69 | LMNA (0.54) | KDM4EHSD17B10KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL17068139 | 0.69 | POLB (0.48) | HSD17B10KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL20612845 | 0.69 | POLB (0.48) | HSD17B10KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL5195336 | 0.68 | MAPT (0.43) | KMT2AMEN1ATMCYP1A2SMN1; SMN2 | |
| SCHEMBL29561442 | 0.68 | ALDH1A1 (0.45) | HSD17B10ALDH1A1MAPT | |
| SCHEMBL29046368 | 0.68 | GAA (0.70) | KDM4EHSD17B10KMT2AMEN1ATM | |
| SCHEMBL15175511 | 0.68 | ALDH1A1 (0.39) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL31320073 | 0.68 | HTR1A (0.41) | KDM4EHSD17B10ALDH1A1LMNA | |
| SCHEMBL31320067 | 0.68 | HTR1A (0.41) | KDM4EHSD17B10ALDH1A1LMNA | |
| SCHEMBL2276952 | 0.67 | FKBP1A (0.54) | KDM4EKMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087485-A1 | 4-AMINOPIPERIDINE DERIVATIVES | BOEHRINGER MARKUS | 2010-04-08 | — | — | US | disclosed |
| US-7683079-B2 | 4-aminopiperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20060135561-A1 | 4-Aminopiperidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087485-A1 | 4-AMINOPIPERIDINE DERIVATIVES | DPP4, GPR119, IAPP | KDM4E 317/4885HSD17B10 843/4885KMT2A 1871/4885 |
| US-20060135561-A1 | 4-Aminopiperidine derivatives | DPP4, GPR119, IAPP | KDM4E 317/4885HSD17B10 843/4885KMT2A 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.